C. DIFFICILE INFECTION CLINICAL TRIALS
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
REBYOTA is a microbiota suspension prepared from human stool which is collected from prescreened and qualified donors, and addresses the GI dysbiosis, which is seen as the root cause of CDI. Unlike fecal microbiota transplantation (FMT), REBYOTA is not intended to treat actual episodes of symptomatic CDI but given only after antibiotic treatment to prevent recurrent CDI. Eligible patients are adults who meet the following criteria:
Diagnosis of recurrent CDI as determined by the treating physician
Completed antibiotic treatment for the presenting recurrent CDI episode
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VE303 FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
A Phase 2, randomized, double-blind, placebo-controlled study of LMN-201 for prevention of C. difficile infection recurrence
